Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

RXRX stock hub

Recursion Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

RXRXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.8B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

RXRX

In the news

Latest news · RXRX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-57.2

P25 -105.6P50 -46.5P75 -3.1

ROIC-34.4

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All RXRX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

210

Groups with data

Currency

USD

Showing 210 of 210 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001601830
Company name	Recursion Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	75629V104
Employees	600
Employees Change	-200%
Employees Change Percent	-25
Enterprise value	$1.2B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-04-16
Isin	US75629V1044
Last refreshed	2026-05-10
Market cap	$1.8B
Market cap category	Small-Cap
Price	$3.32
Price currency	USD
Rev Per Employee	110,680x
Sector	Healthcare
Sic	2836
Symbol	RXRX
Tags	artificial-intelligence
Website	https://www.recursion.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-31.77%
EV Sales Forward	13.06x
EV/Sales	17.77x
FCF yield	-18.49%
P/B ratio	1.72x
P/S ratio	26.53x
PS Forward	19.51x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-428.7M
Net Income	$-559.8M
Net Income Growth Quarters	2%
Net Income Growth Years	0%
Pretax Margin	-849.83%
Profit Per Employee	$-932,960
ROA	-27.66
Roa5y	-27.41
ROCE	-48.38
ROE	-57.16
Roe5y	-56.93
ROIC	-34.44

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-20.78%
Cagr3y	-13.67%
Cagr5y	-34.59%
EPS Growth Quarters	2
EPS Growth Years	1
Revenue Growth	11.07x
Revenue Growth Q	-56.11x
Revenue Growth Years	6x
Revenue Growth3 Y	12.5x
Revenue Growth5 Y	59.35x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.05
Assets	$1.3B
Cash	$654.5M
Current Assets	$709.6M
Current Liabilities	$129.7M
Debt	$72.4M
Debt Equity	$0.07
Equity	$1B
Interest Coverage	-354.3
Liabilities	$314.8M
Long Term Assets	$630M
Long Term Liabilities	$185.1M
Net Cash	$582.1M
Net Cash By Market Cap	$33.03
Net Cash Growth	42.83%
Net Debt Equity	$-0.57
Tangible Book Value	$570.5M
Tangible Book Value Per Share	$1.08
WACC	9.68

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.47
Net Working Capital	$-52.3M
Quick ratio	5.15
Working Capital	$579.9M
Working Capital Turnover	$0.13

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-51.66%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-20.76%
200-day SMA	4.46
3Y total return	-35.66%
50-day SMA	3.39
50-day SMA vs 200-day SMA	50under200
5Y total return	-88.03%
All Time High	42.81
All Time High Change	-92.24%
All Time High Date	2021-07-13
All Time Low	2.8
All Time Low Change	18.57%
All Time Low Date	2026-03-30
ATR	0.2
Beta	1.05
Beta1y	2.86
Beta2y	3.34
Ch YTD	-18.83
High	3.35
High52	7.18
High52 Date	2025-10-20
High52ch	-53.76%
Low	3.2
Low52	2.8
Low52 Date	2026-03-30
Low52ch	18.57%
Ma50ch	-2.04%
Premarket Change Percent	0.92
Premarket Price	$3.3
Premarket Volume	501,669
Price vs 200-day SMA	-25.58%
RSI	46.24
RSI Monthly	38.3
RSI Weekly	40.69
Sharpe ratio	-0.01x
Sortino ratio	0.07
Total Return	-51.66%
Tr YTD	-18.83
Tr1m	4.08%
Tr1w	-2.06%
Tr3m	-16.58%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Count Top	1
Analyst Price Target Top	$8
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.27
Earnings Revenue Estimate	15,863,952x
Earnings Revenue Estimate Growth	7.59x
Operating Income	$-585.3M
Operating margin	-881.3
Price target	$8
Price Target Change	$141
Price Target Change Top	$141

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	513,792,936%
Float Percent	96.8%
Net Borrowing	-8,586,000
Shares Insiders	3.04%
Shares Institutions	63.45%
Shares Out	530,762,198
Shares Qo Q	0.49%
Shares Yo Y	51.66%
Short Float	33.94%
Short Ratio	14
Short Shares	32.86

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-423.2M
Average Volume	11,882,838x
Bv Per Share	1.93
CAPEX	$-4.9M
Ch1m	4.08
Ch1w	-2.06
Ch1y	-20.76
Ch3m	-16.58
Ch3y	-35.66
Ch5y	-88.03
Ch6m	-28.14
Change	1.53%
Change From Open	0.61
Close	3.27
Days Gap	0.92
Depreciation Amortization	84,043,000
Dollar Volume	45,312,073.8
Earnings Date	2026-05-06
Earnings Time	bmo
EBIT	$-585.3M
EBITDA	$-501.2M
EPS	$-1.17
F Score	3
FCF	$-325.8M
FCF EV Yield	-27.61x
FCF Per Share	$-0.61
Financing CF	477,535,000
Fiscal Year End	December
Founded	2,013
Goodwill	160,170,000
Income Tax	$-4.6M
Investing CF	-9,939,000
Ipr	-81.56
Iprfo	-88.93
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-25
Ma150	4.23
Ma150ch	-21.53%
Ma20	3.5
Ma20ch	-5.2%
Net CF	156,023,000
Next Earnings Date	2026-08-04
Open	3.3
Optionable	Yes
Position In Range	80
Post Close	3.32
Postmarket Change Percent	-0.61
Postmarket Price	$3.3
Ppne	157,321,000
Pre Close	3.27
Price Date	2026-05-08
Ptbv Ratio	3.09
Relative Volume	1.15x
Revenue	66,408,000x
SBC By Revenue	146.64x
Share Based Comp	97,380,000
Tax By Revenue	-6.9x
Tr6m	-28.14%
Us State	Utah
Volume	13,648,215
Z Score	0.98

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does RXRX pay a dividend?

Capital-return profile for this ticker.

Performance

RXRX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns RXRX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+63.4%

Float: +96.8% of shares outstanding

Insider ownership

+3.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

RXRX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

46.2

Neutral momentum band

Price vs 200-day MA

-25.6%

50/200-day relationship not available

Beta (5Y)

1.05

Moves roughly with the market

Sharpe ratio

-0.01

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About RXRX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current RXRX stock rating?

Recursion Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full RXRX analysis?

The full report lives at /stocks/RXRX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for RXRX?

The latest report frames RXRX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the RXRX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.